Tin tức & Cập nhật
Lọc theo Chuyên ngành:
KEYNOTE-826: Pembrolizumab + chemo +/- bevacizumab improves PFS and OS in East Asians with cervical cancer
The addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improves progression-free survival (PFS) and overall survival (OS) in East Asian patients with persistent, recurrent or metastatic cervical cancer, according to an exploratory analysis of the final results from the phase III KEYNOTE-826 trial.
KEYNOTE-826: Pembrolizumab + chemo +/- bevacizumab improves PFS and OS in East Asians with cervical cancer
24 Jul 2025
Subcutaneous on par with IV pembrolizumab for NSCLC
Pembrolizumab administered subcutaneously (SC) is noninferior to the intravenous (IV) strategy in terms of overall exposure and trough concentrations, with similar efficacy and consistent safety profiles in patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), reports a study.
Subcutaneous on par with IV pembrolizumab for NSCLC
17 Jul 2025
RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals
A 12-month therapeutic intervention with self-administered abatacept can delay the onset of rheumatoid arthritis (RA) in at-risk individuals for up to 4 years, according to results from the ALTO follow-up study presented at EULAR 2025.